XML 21 R4.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Operating expenses        
Research and development $ 15,900 $ 6,900 $ 43,700 $ 20,100
General and administrative 4,764 2,591 12,016 6,147
Total operating expenses 20,628 9,530 55,752 26,202
Loss from operations (20,628) (9,530) (55,752) (26,202)
Other (expenses) income        
Interest income 3,147 13 8,715 13
Change in fair value of Series B preferred stock tranche rights liability 0 (13,328) 0 (13,356)
Total other income (expense) 3,147 (13,315) 8,715 (13,343)
Net loss before income taxes (17,481) (22,845) (47,037) (39,545)
Income tax expense 0 0 (1) 0
Net loss $ (17,481) $ (22,845) $ (47,038) $ (39,545)
Net Loss per share, basic (in usd per share) $ (1.60) $ (38.23) $ (11.27) $ (70.18)
Net Loss per share, diluted (in usd per share) $ (1.60) $ (38.23) $ (11.27) $ (70.18)
Weighted-average number common shares outstanding, basic (in shares) 10,901,138 597,586 4,174,353 563,483
Weighted-average number common shares outstanding, diluted (in shares) 10,901,138 597,586 4,174,353 563,483
Related Party        
Operating expenses        
Research and development $ 2,310 $ 2,271 $ 7,400 $ 6,511
Nonrelated Party        
Operating expenses        
Research and development $ 13,554 $ 4,668 $ 36,336 $ 13,544